1 **Accelerated approval of non-cancer drugs by the US Food and Drug Administration: A**
2 **protocol for a meta-epidemiological investigation.**

3
4 Kenji Omae^{1,2,3,4}, Akira Onishi⁵, Ethan Sahker^{6,7}, Toshi A Furukawa⁶

5
6 ¹*Department of Innovative Research and Education for Clinicians and Trainees (DiRECT),*
7 *Fukushima Medical University Hospital, Fukushima, Japan*

8 ²*Center for Innovative Research for Communities and Clinical Excellence (CiRC²LE),*
9 *Fukushima Medical University, Fukushima, Japan*

10 ³*Department of Healthcare Epidemiology, Graduate School of Medicine/School of Public*
11 *Health, Kyoto University, Kyoto, Japan*

12 ⁴*Department of Urology, Tokyo Women's Medical University, Tokyo, Japan*

13 ⁵*Department of Rheumatology and Clinical Immunology, Kobe University Graduate School*
14 *of Medicine, Kobe, Japan*

15 ⁶*Department of Health Promotion and Human Behavior, and Department of Clinical*
16 *Epidemiology, Graduate School of Medicine/School of Public Health, Kyoto University,*
17 *Kyoto, Japan*

18 ⁷*Japan Society for the Promotion of Science (JSPS), Overseas Fellowship Division, Tokyo,*
19 *Japan*

20
21 **Key Words:** accelerated approval, market authorization, noncancer drugs, surrogate
22 outcomes, United States Food and Drug Administration

23 **Abstract**

24 The US Food and Drug Administration (FDA) 's accelerated approval program, in
 25 which drugs are approved on the basis of surrogate endpoints, has been a source of
 26 controversy in the context of risk-benefit trade-offs. The FDA recently reported on the
 27 25-year experience with the program and concluded that the low failure rate in post-approval
 28 confirmatory trials was evidence that the program was operating effectively. However, many
 29 studies have revealed manufacturers' poor adherence to obligation of conducting
 30 confirmatory trials, and also concerned the harm and cost of cancer drugs approved through
 31 this program based on the limited evidence. To date, few studies have investigated
 32 accelerated approval of non-cancer drugs. Therefore, the purpose of this study is to review
 33 trends in the FDA's utilization of its accelerated approval program for non-cancer drugs and
 34 clarify the status of fulfillment of social obligations by the FDA and sponsors in the program.
 35 The FDA's documents will be reviewed at Drugs@FDA to identify pre-approval and
 36 confirmatory trials and regulatory updates for drug indications granted accelerated approval
 37 other than cancer treatments. We will further search PubMed, Google/Google Scholar, and
 38 the sponsors' websites to match each identified confirmatory trial to publications in the
 39 medical literature.

40

41 INTRODUCTION

42 For serious or life-threatening diseases, the US Food and Drug Administration
43 (FDA) can approve drugs on the basis of surrogate endpoints that are “reasonably likely to
44 predict clinical benefit,” via its accelerated approval review pathway.¹ Surrogate endpoints
45 consist of markers, including laboratory values, radiographic images, or other physical
46 measurements, that can reflect true clinical endpoints, such as a reduction in patient
47 symptoms or mortality. In 1992, Congress authorized this accelerated approval program as a
48 response to the demand for faster drug development in the context of the HIV/AIDS crisis.²
49 Since then, the program has expanded to include oncology products and drugs for other
50 diseases, now accounting for about 10% of new drug approvals.³

51
52 The accelerated pathway commits drug manufacturers to conduct post-approval
53 trials to confirm the drug’s efficacy and safety for the approved indication. Current FDA
54 guidance requires that the confirmatory study be ongoing during initial drug approval.
55 Confirmatory studies must be adequate and well-controlled to monitor both clinical benefit
56 and risk profile. Manufacturers must also include a statement in the official labeling stating
57 clinical benefit “has not been established” and that confirmatory trials are ongoing. The
58 labeling is revised when those confirmatory trials are completed.

59
60 The accelerated approval program has been a source of controversy, especially in
61 cancer drug approval. Approving drugs on the basis of surrogate endpoints can be risky, as
62 promising surrogates may later be found not to accurately predict actual changes in patient
63 health outcomes. To make matters worse, it can lead to unnecessary and avoidable adverse
64 events such as detrimental side effects or deaths if it is not properly managed. The FDA
65 recently reported on the 25-year experience with the accelerated pathway. The report

66 evaluated 93 oncology indications granted accelerated approval from December 11, 1992,
 67 through May 31, 2017.⁴ The review found that confirmatory trials verified clinical benefit in
 68 51 (55%) of the 93 indications. In 5 cases (5%), approval for an indication was withdrawn
 69 based on post-approval trial findings, and for the remaining 37 (40%) indications,
 70 post-approval evaluations were ongoing. The FDA concluded that the low failure rate in
 71 confirmatory trials was evidence that the accelerated approval pathway was operating
 72 effectively. However, many studies have revealed manufacturers' poor adherence to
 73 obligation of conducting post-approval confirmatory studies, and also concerned the harm
 74 and cost of cancer drugs approved through this pathway based on the limited evidence.⁵⁻⁹
 75 These findings suggest that further efforts and continuous monitoring are needed to properly
 76 implement this program in the context of the risk-benefit trade-off.

77

78 As mentioned above, accelerated approval of cancer drugs has been intensively
 79 studied, while few studies have investigated accelerated approval of non-cancer drugs. Thus,
 80 the purpose of this study is to review trends in the FDA's utilization of its accelerated
 81 approval program for non-cancer drugs and clarify the status of fulfillment of social
 82 obligations by the FDA and sponsors in the program. We will evaluate the extent to which
 83 confirmatory studies were completed, the extent to which accelerated approvals were
 84 converted to regular approvals, and the time between accelerated approval and fulfillment of
 85 post-approval requirements. The frequency of post-market safety-related label modifications
 86 and withdrawals and the publication statuses of completed confirmatory studies will also be
 87 examined.

88

89 **METHODS**

90 **Sample Identification**

We will review publicly available FDA documents (CDER [Center for Drug Evaluation and Research] Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint) to identify all the indications that received accelerated approval by the FDA since 1992.¹⁰ We will collect data on all the molecular entities and original therapeutic biologics approved for the indications other than cancer treatment. As with the previous study on cancer drug,⁶ this study will include drug indications approved up to May 2018, resulting in allowing at least 2 years for the completion and publication of post-approval confirmatory studies.

99

100 Identification of Pre-approval Studies

The clinical studies underlying accelerated approval will be identified and characterized. For all drug indications in the sample, the medical review reports and product labels from the Drugs@FDA database will be examined to identify pre-approval studies that established the drug's efficacy. Drugs@FDA is a publicly available database of all FDA-approved products and contains the approval history for each product, including links to communications from the FDA to the sponsor and product label updates.¹¹ When available, medical review reports will be used to gather information about pre-approval trial characteristics. Medical review reports provide a comprehensive overview of the efficacy and safety of a drug. When medical reviews are not available (as can be the case for supplemental approvals), the product labels that describe the key clinical studies supporting the accelerated approval for a new indication will be used.

112

113 Identification of Post-approval Confirmatory Studies

We will review the FDA's approval letters and medical review reports available in the Drugs@FDA database to identify the post marketing requirements (PMRs), including the

schedule of confirmatory studies, at the time of accelerated approval. Information reported in the FDA’s documents will be used to summarize how the FDA characterized the main limitation of the available data at the time of accelerated approval and whether required confirmatory studies have assessed efficacy, safety, or long-term follow-up.

Two sources of information will be reviewed to determine the status of post-approval study requirements. First, we will search the FDA’s publicly available database of PMRs and commitments,¹² and collect the information on status labels defined by the FDA for post-marketing commitments. Status labels are defined as, (a) “ongoing” – the confirmatory trial is proceeding according to, or ahead of, the original schedule as negotiated between the manufacturer and the FDA, (b) “delayed” – the progression of the confirmatory trial is behind the original schedule, (c) “pending” – the trial has not been initiated and it does not meet the criterion for delayed status, (d) “terminated” – the applicant ended the trial before completion and has not yet submitted a final study report to the FDA, (e) “submitted” – the applicant has concluded or terminated the study, has submitted a final study report to the FDA, but FDA has not yet notified the applicant about commitment fulfillment or release, and (f) “fulfilled” – the FDA is satisfied that the applicant has met the terms of the commitment. Sometimes the FDA will release a manufacturer’s obligation to conduct a post-marketing study because the trial is either no longer feasible or would no longer provide useful information. Such feasibility and utility indications are listed as, (g) “released.”

Second, we will screen ClinicalTrials.gov, a publicly available clinical study registry, for all confirmatory study requirements. Since 2007, Section 801 of the FDA Amendments Act has required the registration of clinical studies subject to FDA regulation, including studies that satisfy post-marketing requirements. For each registered study, the trial registries specify the status (e.g., still recruiting, ongoing but no longer recruiting, completed),

as well as the start and end date. The confirmatory study status, complete or ongoing, per specified timelines in the FDA's approval letters will be assessed. Studies will be considered delayed if the estimated primary completion date in trial registries is at least 1 year later than specified in the FDA approval letters according to the previous study.⁸ When there is a discrepancy between the FDA's public database and ClinicalTrials.gov, information from ClinicalTrials.gov will be used to determine the status of post-approval study requirements.

Three reviewers (AO, ES and KO) will screen the databases independently. Disagreements will be resolved by discussion; otherwise, a fourth independent reviewer (TAF) will arbitrate.

Data Extraction in Pre-approval and Confirmatory Studies

Information extracted from each pre-approval and confirmatory study will include design (randomized vs nonrandomized and the status of allocation concealment in a randomized study), comparators, participant enrollment, and primary end point. Comparators will be classified as active (comparing drugs A vs B), add-on (comparing drugs A + B vs drug B alone), placebo, or none. Drugs tested in single-intervention-group trials will be classified as having no comparators. Type of blinding (double blinded vs single blinded vs open label) will be recorded. Study findings will be summarized in terms of the specified primary endpoint. In confirmatory studies, verification of clinical benefit will be assessed.

Publication Matching of Completed Confirmatory Studies

We will search PubMed, Google/Google Scholar, and the sponsors' websites to match each identified trial to publications in the medical literature. Studies in all languages will be reviewed as abstracts or full texts. Trials identified in the FDA documents and

ClinicalTrials.gov will be matched to publications based on the following characteristics:
study identifier (NCT number and/or trial ID), drug name, sample size, dosing schedules,
arm number, and primary and secondary outcome measures. Publication matching will be
performed independently by three investigators (AO, ES and KO) and disagreements will be
resolved by discussion. If consensus cannot be reached, a fourth independent investigator
(TAF) will arbitrate.

Assessment of Regulatory Outcomes

To determine if drug indications granted accelerated approvals later have their labels
updated, changes to product labels and the accompanying regulatory letters will be reviewed.
The FDA's correspondence with product sponsors on topics related to the approval and
changes in status of their products is publicly available in the Drugs@FDA database. The
Drug Safety-related Labeling Changes (SrLC) database provides approved safety-related
labeling changes from January 2016 forward.¹³ Data prior to January 2016 are available on
the MedWatch website.¹⁴

Statistical Analysis

We will descriptively analyze the trends in the FDA's utilization of its accelerated
approval program for non-cancer drugs over time and determine a timeline of approvals,
post-marketing trial results, and the safety-related label update or withdrawal. We will further
demonstrate the frequency of termination of confirmatory studies and their publication
statuses, the frequency of post-market conversion to regular approvals, and the frequency of
safety-related label modifications and withdrawals. Mann-Whitney U test and chi-square test
will be used to evaluate differences in study features between pre-approval and confirmatory
studies, including enrollment, study design, and primary endpoints. A P-value of <0.05 will

191 be considered statistically significant. Statistical analyses will be conducted using STATA
192 version 16 (Stata Corp LP, College Station, TX, USA).

193

194 Ethical Consideration

195 The protocol for this meta-epidemiological investigation was registered with the
196 University Hospital Medical Information Network (www.umin.ac.jp/ctr/index-j.htm;
197 registration number UMIN000039281). This study will not involve individual patient
198 information; it will involve publicly available trial-level data, and therefore, institutional
199 review board approval will not be required.

200

REFERENCES

1. Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics
<https://www.fda.gov/media/86377/download> Accessed October 7, 2019.
2. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the Food and Drug Administration experience. *J Natl Cancer Inst* 2011; 103: 636-44.
3. Kesselheim AS, Wang B, Franklin JM, Darrow JJ. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study. *BMJ* 2015; 351: h4633.
4. Beaver JA, Howie LJ, Pelosof L, et al. A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. *JAMA Oncol*. 2018;4(6):849-856.
5. Gill J, Prasad V. A reality check of the accelerated approval of immune-checkpoint inhibitors. *Nat Rev Clin Oncol*. 2019. doi: 10.1038/s41571-019-0260-y.
6. Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. *JAMA Intern Med*. 2019;179(7):906-913.
7. DiMagno SSP, Glickman A, Emanuel EJ. Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration. *JAMA Intern Med*. 2019;179(7):922-923.
8. Naci H, Smalley KR, Kesselheim AS. Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug Administration. *JAMA*. 2017;318(7):626-636.
9. Gellad WF, Kesselheim AS. Accelerated Approval and Expensive Drugs - A Challenging

Combination. N Engl J Med. 2017;376(21):2001-2004.

10. CDER Drug and Biologic Accelerated Approvals Based on a Surrogate Endpoint

<https://www.fda.gov/drugs/nda-and-bla-approvals/accelerated-approvals> Accessed May 11, 2020.

11. Drugs@FDA : FDA Approved Drug Products

<https://www.accessdata.fda.gov/scripts/cder/daf/> Accessed May 11, 2020.

12. Postmarket Requirements and Commitments

<https://www.accessdata.fda.gov/scripts/cder/pmc/index.cfm> Accessed May 11, 2020.

13. Drug Safety-related Labeling Changes (SrLC)

<https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/> Accessed May 11, 2020

14. MedWatch Medical Product Safety Information archive

<http://wayback.archive-it.org/7993/20170110235327/http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm> Accessed May 11, 2020